Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt
04:35am, Thursday, 01'st Aug 2024
French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on T
Sanofi CEO Paul Hudson: We have one of the best growth profiles in all of Big Pharma
09:07am, Wednesday, 31'st Jul 2024
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's record demand for Dupixent, state of drug innovation in Europe, company outlook, and more.
Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
04:00pm, Friday, 26'th Jul 2024
Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning poten
Sanofi (SNY) Q2 2024 Earnings Call Transcript
12:51pm, Thursday, 25'th Jul 2024
Sanofi (NASDAQ:SNY ) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Ex
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
11:41am, Thursday, 25'th Jul 2024
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
Press Release: Online availability of Sanofi's half-year financial report for 2024
10:57am, Thursday, 25'th Jul 2024
Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and
Sanofi bumps up full-year forecast after strong Q2 profit
01:37am, Thursday, 25'th Jul 2024
Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year pro
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
12:15pm, Tuesday, 23'rd Jul 2024
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels wit
Stable Blue-Chip Stocks to Buy Before Earnings Season
08:00am, Wednesday, 17'th Jul 2024
Today, we'll explore three stable blue-chip stocks to buy. As the earnings season approaches, Wall Street is getting readyfor potential market volatility.
Sanofi to invest $437 mln in India global centre, double its workforce
07:16am, Wednesday, 17'th Jul 2024
French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workfor
Four Blue Chip Stocks To Buy Now And Hold For Forever
06:13am, Saturday, 13'th Jul 2024
Investors have been running on a high for the last several months as all major U.S.
Sanofi ships U.S. influenza vaccines for the 2024/25 season
04:10pm, Wednesday, 10'th Jul 2024
Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns.
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
10:55am, Tuesday, 09'th Jul 2024
Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.
5 Relatively Secure And Cheap Dividend Stocks To Invest In - July 2024
09:30am, Saturday, 06'th Jul 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
